Neurocrine Biosciences, Inc.
DE ˙ DB ˙ US64125C1099
134,65 € ↑0,30 (0,22%)
2026-06-03
DEL PRIS
SecurityDE:NB3 / Neurocrine Biosciences, Inc.
InstitutionPerpetual Ltd
Latest Disclosed Ownership3,359 shares
Latest Disclosed Value $ 442,515
Perpetual Ltd reports 22.64% increase in ownership of NB3 / Neurocrine Biosciences, Inc.

On April 14, 2026 - Perpetual Ltd filed a 13F-HR form disclosing ownership of 3,359 shares of Neurocrine Biosciences, Inc. (DE:NB3) valued at $375,368 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 20, 2026 disclosing 2,739 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 22.64% during the quarter. The current value of the position is $452,289 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-14 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,359 620 22.64 443 13.92 0.0068
2026-01-20 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,739 2,739 388 0.0056
2025-10-10 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -2,930 -100.00 0 -100.00
2025-07-11 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,930 0 0.00 368 13.58 0.0043
2025-04-24 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,930 -10,171 -77.64 324 -81.88 0.0039
2025-01-17 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,101 541 4.31 1,788 23.57 0.0210
2024-10-09 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,560 6,170 96.56 1,447 64.62 0.0157
2024-07-30 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,390 -410 -6.03 880 -6.19 0.0096
2024-04-16 2024-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 6,800 14 0.21 938 4.81 0.0092
2024-04-10 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,800 14 938 0.0058
2024-02-15 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,786 6,786 894 0.0092
2023-10-10 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -2,268 -100.00 0 -100.00
2023-07-13 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,268 2,268 214 0.0018
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.